Response Genetics, Inc. (the “Company” or “Response Genetics”) announced today that its Board of Directors (the “Board”) has appointed Thomas A. Bologna as Chief Executive Officer (“CEO”), effective as of December 21, 2011. Mr. Bologna was also elected a member and Chairman of the Board, succeeding Kirk K. Calhoun as Chairman. Mr. Calhoun, who will remain a member of the Board, was elected to the newly created position of Lead Director. Denise McNairn, who had been serving as the Company’s Chief Executive Officer on an interim basis since July 22, 2011, will continue to serve as the Company’s Vice President, General Counsel and Secretary.
Mr. Calhoun said: “We are delighted to announce Tom’s appointment as Chairman and CEO given his proven leadership abilities and his extensive experience in the biotechnology industry. He is the ideal leader for Response Genetics as we seek to accelerate the sales and growth of our existing product lines, achieve new research breakthroughs and improve our financial performance.”
Mr. Bologna said: “I am excited to become Chairman and CEO of Response Genetics, which I believe has great potential. I look forward to working with all of our dedicated employees and the Board, as well as reaching out to our shareholders, partners and other stakeholders. With our collective efforts, I believe Response Genetics can become a leading life sciences company while helping the fight against cancer.”
From April 2006 until joining Response Genetics, Mr. Bologna served as President and Chief Executive Officer of Orchid Cellmark, Inc., a NASDAQ-listed corporation and a leading service provider of DNA identity testing. Prior to joining Orchid Cellmark, Mr. Bologna was President, Chief Executive Officer and a member of the board of the venture-backed Quorex Pharmaceuticals, Inc., where he orchestrated a successful sale to Pfizer Inc. Prior to leading Quorex, Mr. Bologna was Chairman of the Board, President and Chief Executive Officer of Ostex International, Inc., a NASDAQ-listed biotechnology company that developed and commercialized disease management products with a focus on osteoporosis. Mr. Bologna oversaw the sale of Ostex to Alere Inc. (formally Inverness Medical Innovations).
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts